Today marked the first day of AACR 2019 in Atlanta. The conference has already been packed with new advancements and data from studies that could significantly impact clinical practice within oncology, such as key data from the TATTON and DART trials. Take a look at some of our highlights below, and tell us your thoughts in the comments.
Remember you can find us at booth #4438, or follow our Twitter updates @OncologyCentral.
Picture of the Day
Visit us at booth 4438 to claim your free tote bag
(Plenary session two: April 1, 8:15 AM–10:15 AM Hall A – Convention Center)
MET inhibitor savolitinib shows promise for EGFR-mutant NSCLC
The addition of the investigational MET inhibitor savolitinib to the EGFR inhibitor osimerinib (Tagrisso®) is beneficial for certain pre-treated patients with EGFR-mutant non-small cell lung cancer (NSCLC), according to results from the TATTON trial.
Ipilimumab, nivolumab combination demonstrates efficacy in high-grade neuroendocrine carcinoma
Results from the DART Phase II clinical trial indicate that a therapeutic combination of the anti-CTLA-4 immunotherapeutic, ipilimumab (Yervoy®), and the anti-PD-1 immunotherapeutic, nivolumab (Opdivo®), may be beneficial to patients with rare, high-grade neuroendocrine carcinoma.
A combination therapy that uses both chemotherapy and CAR-T cells engineered to target the HER2 protein has been found to be safe and showed clinical response in paediatric and adult patients that have advanced HER2+ sarcoma.